Lilly RET targeted drug Selpercatinib initiates Phase III clinical thyroid myelin-like cancer.

On September 1, the Insight database showed that Lilly's new drug, Selpercatinib (a.k.a. LOXO-292), started Phase III clinical treatment for RET mutant thyroid myelin-like cancer.
this clinical trial is the second phase III clinical trial of the drug initiated in China.
clinical trial for advanced or metastasis RET fusion-positive non-small cell lung cancer is currently under way.
from: Insight Database () Selpercatinib is a powerful, oral, highly selective transfection-period reflying (Rearranged Transit, RET) kinase inhibitor developed by Lilly, and the first inhibitor to target RET kinases, which works by inhibiting the activity of abnormal RET kinases.
The drug has been approved by the U.S. FDA for three breakthrough therapies and priority review approvals, and was approved by the U.S. FDA on May 8, 2020 (trade name Retevmo) for the treatment of metastatic, RET-positive non-small cell lung cancer (NSCLC), advanced or metastatic, RET-positive thyroid cancer that requires systematic treatment, and RET mutant thyroid cancer (MTC) that requires systematic treatment.
This clinic is a randomized, open, parallel grouping of international multi-center Phase III clinics designed to compare the progressive, advanced, non-kinase inhibitor treatment, TFFS and other effectiveness indicators in patients with RET mutant MTC (according to reCIST 1.1 standards) and to evaluate its safety and tolerance.
main endpoint indicators are TFFS, the secondary endpoint is PFS, ORR, DoR, OS and other effectiveness indicators, as well as adverse reactions rate and severity of safety indicators, the domestic target group of 60 people.
RET is a relatively rare cancer-causing gene that encodes a receptor, tyrosine kinase, on the long arm of chromosome 10.
genetic mutations, including fusion/rearm and point mutations, lead to overactive RET signals and out-of-control cell growth, are rare drivers of many types of tumors.
RET fusion is present in approximately 2% of non-small cell lung cancer, 10-20% of papyrus thyroid cancer (PTC) and other types of thyroid cancer, and other cancers (such as colorectal cancer) subgroups, point mutations are present in approximately 60% of thyroid myelin cancer (MTC) and 90% of patients with advanced MTC.
, there is a small probability of RET gene mutations in colorectal, breast and pancreatic cancers.
RET fusion/mutation cancers rely primarily on the activation of RET kinases to maintain their proliferation and survival, a dependence commonly known as "carcinogenic gene addiction" that makes these tumors highly sensitive to small molecule inhibitors targeting RET.
However, the development of RET highly selective targeted drugs is very difficult, in the past patients with RET mutations mainly use chemotherapy or multi-target targeted drugs (e.g. cabodinib, van der Thani), the efficacy is not good, and the side effects are greater.
Iserpercatinib is the first highly selective drug to target RET mutations or fusions, created new therapeutic hopes for patients carrying such gene mutations/fusions.
approved by the FDA based on phase I/II clinical trial LIBRETTO-001 data.
the trial involved three types of tumor patients and assessed Selpercatinib's role in RET fusion mutations in non-small cell lung and thyroid cancer.
results showed that in 105 adult patients with RET fusion-positive non-small cell lung cancer who had underwent platinum chemotherapy, the total remission rate (ORR) was 64% and 81% of the remission duration lasted at least 6 months.
in 19 patients with RET fusion-positive thyroid cancer who were treated with radioactive iodine and received another systemic treatment, the total remission rate (ORR) was 79% and 87% of the remission duration lasted at least 6 months.
in 55 patients with advanced or metastatic RET mutation thyroid myelin cancer who had previously received Cabodini Cabozantinib and/or Vandertani Vandetanib, the total remission rate (ORR) was 69% and 76% of the remissions lasted at least 6 months.
August 27, Lilly Pharmaceuticals announced that NEJM had released the results of the registered clinical trial.
According to the Insight database, there are currently three clinical trials conducted in China by Selpercatinib, including advanced or metastatic RET fusion positive non-small cell lung cancer and RET mutation advanced myeloma (i.e., the clinical trial initiated this time).
.